Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
08/10/2026 13:22
BUZZ-Pacira BioSciences jumps on $1.65 billion Viatris buyout deal ** Shares of Pacira BioSciences PCRX.O rise 44% to $36.30 premarket
** Viatris VTRS.O to buy Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share
** The offer price represents a premium of about 44.8% to Pacira's last closing price of $25.20
** The deal adds Pacira's non-opioid pain drugs Exparel and Zilretta to Viatris' portfolio
** The companies expect the deal to close by the end of 2026
** As of last close, PCRX down 2.6% YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal